Metyrapone

Drug Profile

Metyrapone

Alternative Names: Cormeto; Metirapona; Metopiron; Metopirone; Metycor; SU 4885

Latest Information Update: 10 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer HRA Pharma; Novartis
  • Class Antidepressants; Antihormones; Diagnostic agents; Pyridines
  • Mechanism of Action Steroid 11-beta-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Adrenal insufficiency; Cushing syndrome; Hyperaldosteronism

Most Recent Events

  • 08 Mar 2017 No recent reports of development identified - Preregistration for Adrenal insufficiency (Diagnosis), Cushing's syndrome (Diagnosis) and endogenous Cushing's syndrome in Austria, Luxembourg (PO)
  • 07 Mar 2017 Preregistration for endogenous Cushing's syndrome is ongoing in Germany, Spain and Belgium (PO)
  • 07 Mar 2017 Launched for Adrenal insufficiency (Diagnosis), Cushing's syndrome (Diagnosis) and endogenous Cushing's syndrome in Norway (PO) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top